Compare GlobalFoundries Inc. Ordinary Shares (GFS) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance

GlobalFoundries (GFS) trades at $46.70, down 3.39% on the day, with technical indicators showing a neutral to bearish short-term bias. The company maintains solid fundamentals with $6.79B revenue and 10.32% net margin, though profitability declined year-over-year. Recent catalysts include a landmark $21B Japan-backed fab expansion and strategic partnerships with TSMC and Marvell for AI-related semiconductor production, positioning GFS for long-term growth in the semiconductor sector.

While near-term technical weakness persists, GFS's strategic positioning in AI infrastructure and substantial government-backed expansion create compelling long-term opportunities. Risks include execution challenges with massive capital projects and semiconductor cycle volatility. With 57.9% analyst buy ratings and a $79.69 consensus target representing 71% upside, Wall Street remains optimistic about GFS's growth trajectory despite current market softness.

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.